

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**CHARMACY PHARMACEUTICAL CO., LTD.**

創美藥業股份有限公司

*(A joint stock limited liability company established in the PRC)*

**(Stock Code: 2289)**

**INSIDE INFORMATION  
PROPOSED PARTICIPATION IN  
THE H SHARE FULL CIRCULATION PROGRAMME  
BY THE COMPANY**

This announcement is made by Charmacy Pharmaceutical Co., Ltd. \* (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (CSRC Announcement [2019] No. 22) (《H股公司境內未上市股份申請“全流通”業務指引》(證監會公告[2019]22號)) (the “**Guidelines**”) issued by the China Securities Regulatory Commission (the “**CSRC**”) on 14 November 2019 regarding the procedures of application by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board of directors (the “**Board**”) of the Company is pleased to announce that the Company has submitted an application (the “**Application**”) to the CSRC on 15 February 2022 in respect of the conversion of all of its domestic shares (the “**Unlisted Shares**”) into H shares (the “**H**

**Shares**”) of the Company. Upon obtaining all the relevant approvals (including the approvals from the CSRC and the Stock Exchange) and having complied with all the applicable laws, regulations and rules, such Unlisted Shares will be converted into H Shares, and the Company will apply for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”). Pursuant to the articles of association of the Company, no further shareholders’ meeting or class meeting is required to be convened to approve the Conversion and Listing.

As at the date of this announcement, the Company has not received approval from the CSRC in respect of the Application and the details of implementation plan of the Conversion and Listing have not been finalised. The Company will make further announcements on the progress and details of the Application as and when appropriate.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Shantou, the PRC, 15 February 2022

*As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Mr. Lin Zhixiong; the non-executive Director is Mr. Li Weisheng; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*